Top Analyst Reports For Alphabet, Berkshire Hathaway & Nike
Zacks Investment Research | Jun 27, 2017 01:53AM ET
Tuesday June 27 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc (NASDAQ:GOOGL), Berkshire Hathaway Inc. (NYSE:BRKa) (BRK.B) and Nike Inc (NKE).These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Today's Must Read/h6
Featured Reports/h6
Per the Zacks analyst, the acquisition of E-Plus and other business strategies boosts Telefonica's growth prospects.
The Zacks analyst expects Glaxo's new products to continue performing well. However, top-selling drug Advair is expected to face generic competition in the U.S soon which can hurt sales.
Per the Zacks Analyst, the gradual ease in BofA's margin pressure with rising rates and loan demand will likely aid top-line growth, lessening risks related to mortgage fee growth concerns.
Per the analyst, solid harsh environment applications sales will continue to drive TEL Connectivity's margins. Also, the recent Creganna & Intercontec buyouts bode well for its Industrial segment.
Per the Zacks analyst, fiscal 2017 budget's focus on funding for submarines will boost General Dynamics' growth. Jet sales growth at the Gulfstream business also bolsters its revenue expansion.
The covering analyst is impressed by the strength of the company's intermodal unit.
The Zacks analyst is bullish on Varian's strong presence in Oncology and Proton therapy space. Also focus on emerging markets would aid growth.
Per the Zacks analyst, the acquisition of E-Plus and other business strategies boosts Telefonica's growth prospects.
The Zacks analyst expects Glaxo's new products to continue performing well. However, top-selling drug Advair is expected to face generic competition in the U.S soon which can hurt sales.
Per the Zacks Analyst, the gradual ease in BofA's margin pressure with rising rates and loan demand will likely aid top-line growth, lessening risks related to mortgage fee growth concerns.
Per the analyst, solid harsh environment applications sales will continue to drive TEL Connectivity's margins. Also, the recent Creganna & Intercontec buyouts bode well for its Industrial segment.
Per the Zacks analyst, fiscal 2017 budget's focus on funding for submarines will boost General Dynamics' growth. Jet sales growth at the Gulfstream business also bolsters its revenue expansion.
The covering analyst is impressed by the strength of the company's intermodal unit.
The Zacks analyst is bullish on Varian's strong presence in Oncology and Proton therapy space. Also focus on emerging markets would aid growth.
New Upgrades/h6
The Zacks analyst remains upbeat about McDonald's efforts to boost traffic through digital enhancements, focus on delivery and accelerated deployment of Experience of the Future restaurants in the U.S
The Zacks analyst feels that DuPont's actions to cut operational costs should continue to lend support to its earnings. The mega-merger with Dow Chemical (NYSE:DOW) should also create significant synergies.
Per the Zacks analyst, Coca-Cola's $3.8 billion cost-saving plan covering optimization of global supply chain, enhanced global marketing and innovation, and operating expense leverage will fuel growth
The Zacks analyst remains upbeat about McDonald's efforts to boost traffic through digital enhancements, focus on delivery and accelerated deployment of Experience of the Future restaurants in the U.S
The Zacks analyst feels that DuPont's actions to cut operational costs should continue to lend support to its earnings. The mega-merger with Dow Chemical (NYSE:DOW) should also create significant synergies.
Per the Zacks analyst, Coca-Cola's $3.8 billion cost-saving plan covering optimization of global supply chain, enhanced global marketing and innovation, and operating expense leverage will fuel growth
New Downgrades/h6
Baker Hughes has huge exposure to the North American market from where it generates majority of its sales. Any disruption in the continent will affect its financials, according to the Zacks analyst.
Per the Zacks analyst, the declining price of used trucks, primarily due to higher supply, is adversely affecting the sales of PACCAR.
The Zacks analyst believes that Lilly's sales will continue to remain under pressure due to loss of exclusivity for many drugs. Key cancer drug Alimta will continue to be impacted by competition.
Baker Hughes has huge exposure to the North American market from where it generates majority of its sales. Any disruption in the continent will affect its financials, according to the Zacks analyst.
Per the Zacks analyst, the declining price of used trucks, primarily due to higher supply, is adversely affecting the sales of PACCAR.
The Zacks analyst believes that Lilly's sales will continue to remain under pressure due to loss of exclusivity for many drugs. Key cancer drug Alimta will continue to be impacted by competition.
Get The News You Want
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.